Nanosonics Ltd (ASX: NAN)
Analysts at UBS have retained their buy rating and $7.20 price target on this infection control company’s shares following the release of its trading update. The broker notes that Nanosonics’ has had a better start to FY 2021 than it was expecting, with strong quarter on quarter growth in consumables. And while the broker expects its first half result to be soft, it remains positive on its long term prospects. The broker believes Nanosonics is an example of a high-quality structural growth story, particularly in a post-COVID world which is likely to have a greater focus on infection prevention. This price target implies potential upside of almost 26%.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.82 |
Change
-0.010(0.26%) |
Mkt cap ! $1.159B | |||
| Open | High | Low | Value | Volume |
| $3.83 | $3.85 | $3.80 | $470.9K | 122.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 2078 | $3.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.82 | 1435 | 13 |
View Market Depth
| Last trade - 12.46pm 21/07/2025 (20 minute delay) ? |
| NAN (ASX) Chart |